Colan M. Ho-Yen
C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?
Ho-Yen, Colan M.; Green, Andrew R.; Brentnall, Adam R.; Rakha, Emad A.; Ellis, Ian O.; Kermorgant, Stephanie; Jones, J. L.
Authors
Dr Andy Green ANDREW.GREEN@NOTTINGHAM.AC.UK
ASSOCIATE PROFESSOR
Adam R. Brentnall
Professor EMAD RAKHA Emad.Rakha@nottingham.ac.uk
PROFESSOR OF BREAST CANCER PATHOLOGY
Ian O. Ellis
Stephanie Kermorgant
J. L. Jones
Abstract
BACKGROUND
Basal‐like (BL) breast cancer is an aggressive form of breast cancer with limited treatment options. Recent work has identified BL breast cancer as a biologically distinct form of triple‐negative breast cancer, with a worse outlook. The receptor tyrosine kinase c‐Met is a novel therapeutic target associated with reduced survival in breast cancer. Few studies have specifically addressed the association between c‐Met and molecular subtype of breast cancer, yet this is a key consideration when selecting patients for clinical trials. The aim of this study is to evaluate c‐Met expression in a large cohort of invasive breast cancers and in particular, its correlation with molecular subtype.
METHODS
Immunohistochemistry for c‐Met was performed and evaluated on 1274 invasive breast cancers using tissue microarray technology. The c‐Met scores were correlated with molecular subtype, survival, and other standard clinicopathological prognostic factors.
RESULTS
Multivariate logistic regression showed c‐Met was independently associated with BL status (odds ratio = 6.44, 95% confidence interval = 1.74‐23.78, P = .005). There was a positive correlation between c‐Met and Her2 (P = .005) and an inverse correlation with tumor size (P [less than] .001). C‐Met was an independent poor prognostic factor at Cox regression analysis in all subtypes (hazard ratio = 1.85, 95% confidence interval = 1.07‐3.19, P = .027) and there was a trend toward reduced survival in BL tumors overexpressing c‐Met, but this was not significant.
CONCLUSIONS
C‐Met is independently associated with BL breast cancer. In the future, patients with BL tumors should be included in clinical trials of anti‐c‐Met therapy.
Citation
Ho-Yen, C. M., Green, A. R., Brentnall, A. R., Rakha, E. A., Ellis, I. O., Kermorgant, S., & Jones, J. L. (2014). C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?. Cancer, 120(2), 163-171. https://doi.org/10.1002/cncr.28386
Journal Article Type | Article |
---|---|
Acceptance Date | Aug 20, 2013 |
Online Publication Date | Oct 21, 2013 |
Publication Date | Jan 15, 2014 |
Deposit Date | Oct 17, 2018 |
Journal | Cancer |
Print ISSN | 0008-543X |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 120 |
Issue | 2 |
Pages | 163-171 |
DOI | https://doi.org/10.1002/cncr.28386 |
Public URL | https://nottingham-repository.worktribe.com/output/1172720 |
Publisher URL | https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.28386 |
You might also like
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Epitranscriptomic mechanisms of androgen signalling and prostate cancer
(2024)
Journal Article
Stromal lymphocytes are associated with upgrade of B3 breast lesions
(2024)
Journal Article
The characteristics and prognostic significance of histone H1 expression in breast cancer
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search